The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism ("HI"). The news, analyst moves, and severe market reaction have prompted national shareholders rights firm Hagens Berman to open an investigation into whether Rezolute may have previously misled investors about erso's efficacy and commercial prospects. SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as ...

The firm urges investors in Rezolute who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Visit: www.hbsslaw.com/investor-fraud/rzlt Contact the Firm Now: [email protected] 844-916-0895 Rezolute, Inc. (RZLT) Investigation: As recently as mid-November, Rezolute assured investors that "in both the real-world setting as well as in clinical studies, erso has shown the potential to subst ...

SAN FRANCISCO--(BUSINESS WIRE)--On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug ("erso†). The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism ("HI†). The news, analyst moves, and severe market reaction have prompted national shareholders rights firm Hagens Berman to open an investiga ...